ErVimmune
ErVimmune is a French biotechnology company specializing in next-generation cancer immunotherapies. They focus on developing cancer vaccines and T cell-based therapies that target non-conventional, shared tumor antigens, particularly in cold tumors. Their proprietary AI-driven platform identifies and validates these targets, including those derived from human endogenous retroviruses (HERVs), using proteomics and immunology assays. The company is at a preclinical stage, founded in October 2019, and has received support from BPIFrance, Cancéropôle Lyon Auvergne-Rhône-Alpes, Agence Nationale de la Recherche, and Seventure. ErVimmune has also secured funding and awards from various European and French initiatives, including the EIC Accelerator and the France 2030 plan, positioning them for clinical development.
ErVimmune
ErVimmune is a French biotechnology company specializing in next-generation cancer immunotherapies. They focus on developing cancer vaccines and T cell-based therapies that target non-conventional, shared tumor antigens, particularly in cold tumors. Their proprietary AI-driven platform identifies and validates these targets, including those derived from human endogenous retroviruses (HERVs), using proteomics and immunology assays. The company is at a preclinical stage, founded in October 2019, and has received support from BPIFrance, Cancéropôle Lyon Auvergne-Rhône-Alpes, Agence Nationale de la Recherche, and Seventure. ErVimmune has also secured funding and awards from various European and French initiatives, including the EIC Accelerator and the France 2030 plan, positioning them for clinical development.